Vivek Subbiah shared a post on LinkedIn:

”Talk about shaking the field of cancer research- cracking KRAS!

Not one but TWO back-to-back NATURE papers published concurrently with the Annual meeting of American Association for Cancer Research 2024!  

Such a delight to meet with Mallika Singh to discuss the clinical translation aspects of KRAS targeting. Congratulations to Dr. Singh 2X papers on characterization of Revolution Medicines’ RAS(ON) multiRAS inhibitor.”

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.
Tumor-selective activity of RAS-GTP inhibition in pancreatic cancer.
Source: Vivek Subbiah/LinkedIn

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.